Vanguard Group Inc Mirati Therapeutics, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $16.5 Million - $24.5 Million	-392,939 Reduced 6.89%	5,306,693 $312 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $20.1 Million - $32.7 Million	721,357 Added 14.49%	5,699,632 $248 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $2.57 Million - $3.52 Million	-71,100 Reduced 1.41%	4,978,275 $180 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $2.76 Million - $4.1 Million	75,487 Added 1.52%	5,049,375 $188 Million
Q4 2022 Feb 10, 2023	BUY	$41.27 - $98.62 $10.1 Million - $24.2 Million	245,589 Added 5.19%	4,973,888 $225 Million

Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $10.7 Million - $15.6 Million	180,278 Added 3.96%	4,728,299 $330 Million
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $2.55 Million - $5.78 Million	65,211 Added 1.45%	4,548,021 $305 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $3.32 Million - $6.62 Million	43,833 Added 0.99%	4,482,810 $369 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $39.8 Million - $57.3 Million	301,120 Added 7.28%	4,438,977 $651 Million
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $453,734 - $609,363	3,434 Added 0.08%	4,137,857 $732 Million
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $595 Million - $743 Million	4,134,423 New	4,134,423 $668 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.